NCT06616844View on ClinicalTrials.gov

IDEAL: Efficacy of Porcine Placental Extracellular Matrix Augmented Plus Standard of Care (SOC) Versus SOC Alone for the Management of Diabetic Foot Ulcers

NARecruitingINTERVENTIONAL
Enrollment

194

Participants

Timeline

Start Date

February 12, 2025

Primary Completion Date

February 28, 2026

Study Completion Date

July 31, 2026

Conditions
Wound HealUlcer
Interventions
DEVICE

InnovaMatrix® AC

SOC plus weekly application of the study device

Trial Locations (9)

11042

RECRUITING

Northwell Health Comprehensive Wound Healing Center, New Hyde Park

21742

RECRUITING

US-FAS, Hagerstown

27609

RECRUITING

US-FAS, Raleigh

33015

NOT_YET_RECRUITING

Dinamo Research and Diagnostic Center, Hialeah

47456

RECRUITING

Indiana Foot & Ankle, Jasper

90010

RECRUITING

Angel City Research, Los Angeles

92081

RECRUITING

ILD Research Center, Vista

94115

RECRUITING

Center for Clinical Research, San Francisco

02118

NOT_YET_RECRUITING

Boston Medical Center, Boston

Sponsors

Lead Sponsor

ConvaTec Inc.
All Listed Sponsors
lead

ConvaTec Inc.

INDUSTRY

NCT06616844 - IDEAL: Efficacy of Porcine Placental Extracellular Matrix Augmented Plus Standard of Care (SOC) Versus SOC Alone for the Management of Diabetic Foot Ulcers | Biotech Hunter | Biotech Hunter